Testing effectiveness (Phase 2)Study completedNCT02335918
What this trial is testing
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Who this might be right for
Squamous Cell Carcinoma of the Head and Neck (SCCHN)Ovarian Carcinoma-Enrollment CompletedColorectal Cancer (CRC)-Enrollment Completed+2 more
Celldex Therapeutics 175